本帖最后由 老马 于 2013-3-13 13:43 编辑
* I1 S! W2 f0 |
5 l, U3 \; U: d8 p1 R- y健择（吉西他滨）+顺铂+阿瓦斯汀* B9 n8 Y2 v8 `# |# w" t# M
Gemzar +Cisplatin + Avastin, Z q4 g t: u" z6 Q
http://annonc.oxfordjournals.org/content/21/9/1804.full" |. E( ^% C& h2 U" o% L& D2 K1 z
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) ' R9 q" L' n: r4 @" P2 J
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. / f+ ]2 L( e; `
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
2 g9 \! f8 U, @8 Y
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 245)
, |6 }$ a; k! l4 |! F, U/ ]% R! M0 y
华为网盘附件：
# _5 T, n0 w" n8 w! Z J【华为网盘】ava.JPG# e8 Z2 L/ S8 l2 A$ X5 q
|
显身卡
